Fmr LLC Holds Position in Dimension Therapeutics, Inc. (NASDAQ:DMTX)

Fmr LLC held its stake in shares of Dimension Therapeutics, Inc. (NASDAQ:DMTX) during the first quarter, according to its most recent disclosure with the SEC. The fund owned 4,893,322 shares of the biotechnology company’s stock at the end of the first quarter. Fmr LLC owned approximately 0.20% of Dimension Therapeutics worth $8,563,000 at the end of the most recent reporting period.

Separately, Renaissance Technologies LLC purchased a new stake in shares of Dimension Therapeutics during the fourth quarter worth $236,000. Hedge funds and other institutional investors own 74.59% of the company’s stock.

Dimension Therapeutics, Inc. (NASDAQ:DMTX) opened at 1.35 on Thursday. The firm’s market cap is $33.81 million. The company’s 50-day moving average price is $1.34 and its 200-day moving average price is $1.85. Dimension Therapeutics, Inc. has a 52-week low of $1.05 and a 52-week high of $9.98.

Dimension Therapeutics (NASDAQ:DMTX) last issued its quarterly earnings data on Wednesday, May 10th. The biotechnology company reported ($0.54) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by $0.02. Dimension Therapeutics had a negative return on equity of 80.04% and a negative net margin of 412.27%. The business had revenue of $3.62 million for the quarter. Analysts predict that Dimension Therapeutics, Inc. will post ($2.17) EPS for the current year.

WARNING: “[[title]]” was posted by [[site]] and is the property of of [[site]]. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at [[permalink]].

A number of equities research analysts have recently weighed in on DMTX shares. Zacks Investment Research downgraded Dimension Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, May 11th. Citigroup Inc. downgraded Dimension Therapeutics from a “buy” rating to a “neutral” rating and set a $1.50 price target for the company. in a report on Friday, May 12th. Canaccord Genuity reduced their price objective on Dimension Therapeutics from $20.00 to $12.00 and set a “buy” rating for the company in a research report on Wednesday, June 28th. Finally, Cantor Fitzgerald set a $3.00 price objective on Dimension Therapeutics and gave the company a “hold” rating in a research report on Saturday, June 10th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $5.88.

Dimension Therapeutics Company Profile

Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).

Want to see what other hedge funds are holding DMTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dimension Therapeutics, Inc. (NASDAQ:DMTX).